MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Phase 2 Recruiting
132 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
CARTITUDE-10
Phase 2 Recruiting
60 enrolled
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Phase 2 Recruiting
24 enrolled
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 Recruiting
70 enrolled
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Phase 2 Recruiting
170 enrolled
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Phase 2 Recruiting
25 enrolled
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Phase 2 Recruiting
85 enrolled
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Phase 2 Recruiting
65 enrolled
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Phase 2 Recruiting
209 enrolled
ALPHA3
Phase 2 Recruiting
250 enrolled
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 Recruiting
60 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
120 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
ENABLE-2
Phase 2 Recruiting
60 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Phase 2 Recruiting
50 enrolled
TIL Therapy in cSCC and MCC
Phase 2 Recruiting
14 enrolled
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Recruiting
44 enrolled
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
396 enrolled
ADAPT
Phase 2 Recruiting
60 enrolled
FLUCLORIC
Phase 2 Recruiting
302 enrolled
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Phase 2 Recruiting
20 enrolled
CY-MET-RIC
Phase 2 Recruiting
82 enrolled
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 2 Recruiting
102 enrolled
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Phase 2 Recruiting
35 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 Recruiting
20 enrolled
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Phase 2 Recruiting
68 enrolled
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Phase 2 Recruiting
240 enrolled
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Phase 2 Recruiting
35 enrolled
BMT-13
Phase 2 Recruiting
38 enrolled
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 Recruiting
20 enrolled
DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 Recruiting
248 enrolled
PragmaTIL
Phase 2 Recruiting
40 enrolled
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
Phase 2 Recruiting
50 enrolled
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Phase 2 Recruiting
10 enrolled
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Phase 2 Recruiting
30 enrolled
HLA
Phase 2 Recruiting
114 enrolled
RRTCLAlloSCT
Phase 2 Recruiting
34 enrolled